Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

Developing and maintaining collaborative practice: Exploring perspectives from dietetics and speech pathology about 'what works well'.

Croker A, Brown L, Little A, Squires K, Crowley E.

Nutr Diet. 2019 Feb;76(1):28-37. doi: 10.1111/1747-0080.12506. Epub 2018 Dec 25.

PMID:
30585376
2.
3.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.

Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA; DRIVE-AHEAD Study Group.

Clin Infect Dis. 2019 Feb 1;68(4):535-544. doi: 10.1093/cid/ciy540.

4.

14-3-3γ binds regulator of G protein signaling 14 (RGS14) at distinct sites to inhibit the RGS14:Gαi-AlF4- signaling complex and RGS14 nuclear localization.

Gerber KJ, Squires KE, Hepler JR.

J Biol Chem. 2018 Sep 21;293(38):14616-14631. doi: 10.1074/jbc.RA118.002816. Epub 2018 Aug 9.

PMID:
30093406
5.

Decoding: It's Not All About the Letters.

Squires KE.

Lang Speech Hear Serv Sch. 2018 Jul 5;49(3):395-408. doi: 10.1044/2018_LSHSS-17-0104.

PMID:
29978208
6.

Genetic Analysis of Rare Human Variants of Regulators of G Protein Signaling Proteins and Their Role in Human Physiology and Disease.

Squires KE, Montañez-Miranda C, Pandya RR, Torres MP, Hepler JR.

Pharmacol Rev. 2018 Jul;70(3):446-474. doi: 10.1124/pr.117.015354. Review.

PMID:
29871944
7.

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial.

Cahn P, Sax PE, Squires K, Molina JM, Ratanasuwan W, Rassool M, Bloch M, Xu X, Zhou Y, Homony B, Hepler D, Teppler H, Hanna GJ, Nguyen BY, Greaves W; ONCEMRK Study Group.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):589-598. doi: 10.1097/QAI.0000000000001723.

8.

Improving Narrative Production in Children With Language Disorders: An Early-Stage Efficacy Study of a Narrative Intervention Program.

Gillam SL, Olszewski A, Squires K, Wolfe K, Slocum T, Gillam RB.

Lang Speech Hear Serv Sch. 2018 Apr 5;49(2):197-212. doi: 10.1044/2017_LSHSS-17-0047.

PMID:
29621800
9.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group.

Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25.

PMID:
29592840
10.

Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.

Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H.

J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):209-213. doi: 10.1097/QAI.0000000000001663.

PMID:
29481486
11.

Notes from the Field: Monitoring Out-of-State Patients During a Hurricane Response Using Syndromic Surveillance - Tennessee, 2017.

Wiedeman C, Shaffner J, Squires K, Leegon J, Murphree R, Petersen PE.

MMWR Morb Mortal Wkly Rep. 2017 Dec 15;66(49):1364-1365. doi: 10.15585/mmwr.mm6649a6. No abstract available.

12.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group.

Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.

PMID:
28918877
13.

Regulator of G protein signaling 14 (RGS14) is expressed pre- and postsynaptically in neurons of hippocampus, basal ganglia, and amygdala of monkey and human brain.

Squires KE, Gerber KJ, Pare JF, Branch MR, Smith Y, Hepler JR.

Brain Struct Funct. 2018 Jan;223(1):233-253. doi: 10.1007/s00429-017-1487-y. Epub 2017 Aug 3.

14.

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.

Squires K, Bekker LG, Katlama C, Yazdanpanah Y, Zhou Y, Rodgers AJ, DiNubile MJ, Sklar PA, Leavitt RY, Teppler H.

Open Forum Infect Dis. 2017 Feb 28;4(1):ofw047. doi: 10.1093/ofid/ofw047. eCollection 2017 Winter.

15.

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.

Squires KE, Young B, Santiago L, Dretler RH, Walmsley SL, Zhao HH, Pakes GE, Ross LL, Shaefer MS.

HIV AIDS (Auckl). 2017 Mar 3;9:51-61. doi: 10.2147/HIV.S108756. eCollection 2017.

16.

Norepinephrine regulates cocaine-primed reinstatement via α1-adrenergic receptors in the medial prefrontal cortex.

Schmidt KT, Schroeder JP, Foster SL, Squires K, Smith BM, Pitts EG, Epstein MP, Weinshenker D.

Neuropharmacology. 2017 Jun;119:134-140. doi: 10.1016/j.neuropharm.2017.04.005. Epub 2017 Apr 6.

17.

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.

Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, Avihingsanon A, Koenig E, Jiang S, White K, Cheng A, Szwarcberg J, Cao H.

Lancet HIV. 2016 Sep;3(9):e410-e420. doi: 10.1016/S2352-3018(16)30016-9. Epub 2016 May 27.

18.

Human Bacterial Artificial Chromosome (BAC) Transgenesis Fully Rescues Noradrenergic Function in Dopamine β-Hydroxylase Knockout Mice.

Cubells JF, Schroeder JP, Barrie ES, Manvich DF, Sadee W, Berg T, Mercer K, Stowe TA, Liles LC, Squires KE, Mezher A, Curtin P, Perdomo DL, Szot P, Weinshenker D.

PLoS One. 2016 May 5;11(5):e0154864. doi: 10.1371/journal.pone.0154864. eCollection 2016.

19.

Roles for Regulator of G Protein Signaling Proteins in Synaptic Signaling and Plasticity.

Gerber KJ, Squires KE, Hepler JR.

Mol Pharmacol. 2016 Feb;89(2):273-86. doi: 10.1124/mol.115.102210. Epub 2015 Dec 11. Review.

20.

Effects of Bileaflet Mechanical Mitral Valve Rotational Orientation on Left Ventricular Flow Conditions.

Westerdale JC, Adrian R, Squires K, Chaliki H, Belohlavek M.

Open Cardiovasc Med J. 2015 Jun 26;9:62-8. doi: 10.2174/1874192401509010062. eCollection 2015.

21.

Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.

Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK.

Cancer. 2015 Oct 1;121(19):3444-51. doi: 10.1002/cncr.29392. Epub 2015 Aug 24.

22.

Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.

Young B, Squires KE, Tashima K, Henry K, Schneider S, LaMarca A, Zhao HH, Ross LL, Shaefer MS.

HIV Clin Trials. 2015 Aug;16(4):125-9. doi: 10.1179/1528433614Z.0000000017. Epub 2015 Jul 2. No abstract available.

PMID:
26133089
23.

An innovative dietetic student placement model in rural new South wales, australia.

Brown LJ, Macdonald-Wicks L, Squires K, Crowley E, Harris D.

J Allied Health. 2015 Summer;44(2):117-22.

PMID:
26046121
24.

Impact of APOBEC Mutations on CD8+ T Cell Recognition of HIV Epitopes Varies Depending on the Restricting HLA.

Squires KD, Monajemi M, Woodworth CF, Grant MD, Larijani M.

J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):172-8. doi: 10.1097/QAI.0000000000000689.

PMID:
26035050
25.

Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.

Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, Wilson CM, Agwu A, Emmanuel P, Price G, Hudey S, Goodenow MM, Sleasman JW; Adolescent Trials Network for HIVAIDS Interventions.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):52-60. doi: 10.1097/QAI.0000000000000549.

26.

Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.

Markowitz M, Zolopa A, Squires K, Ruane P, Coakley D, Kearney B, Zhong L, Wulfsohn M, Miller MD, Lee WA.

J Antimicrob Chemother. 2014 May;69(5):1362-9. doi: 10.1093/jac/dkt532. Epub 2014 Feb 6.

PMID:
24508897
27.

Story retelling by bilingual children with language impairments and typically developing controls.

Squires KE, Lugo-Neris MJ, Peña ED, Bedore LM, Bohman TM, Gillam RB.

Int J Lang Commun Disord. 2014 Jan-Feb;49(1):60-74. doi: 10.1111/1460-6984.12044. Epub 2013 Aug 31.

28.

High-frequency oscillatory ventilation with low oscillatory frequency in pulmonary interstitial emphysema.

Squires KA, De Paoli AG, Williams C, Dargaville PA.

Neonatology. 2013;104(4):243-9. doi: 10.1159/000353376. Epub 2013 Sep 21.

PMID:
24060678
29.

Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey.

Squires K, Feinberg J, Bridge DA, Currier J, Ryan R, Seyedkazemi S, Dayaram YK, Mrus J.

AIDS Patient Care STDS. 2013 Jun;27(6):352-62. doi: 10.1089/apc.2013.0015. Epub 2013 May 23.

30.

Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.

Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE.

Clin Infect Dis. 2013 Sep;57(5):735-44. doi: 10.1093/cid/cit319. Epub 2013 May 10.

31.

Discussion: 'Congenital hypogonadisms impair quality of life and sexual function,' by Ros et al.

Robbins CC, Wolfe M, Squires K, Jungheim E, Weiner L.

Am J Obstet Gynecol. 2013 Jun;208(6):e1-3. doi: 10.1016/j.ajog.2013.04.005. Epub 2013 Apr 6.

PMID:
23571134
32.

Bone health and human immunodeficiency virus infection.

Schafer JJ, Manlangit K, Squires KE.

Pharmacotherapy. 2013 Jun;33(6):665-82. doi: 10.1002/phar.1257. Epub 2013 Apr 1. Review.

PMID:
23553497
33.

The course of lichen sclerosus diagnosed prior to puberty.

Focseneanu MA, Gupta M, Squires KC, Bayliss SJ, Berk D, Merritt DF.

J Pediatr Adolesc Gynecol. 2013 Jun;26(3):153-5. doi: 10.1016/j.jpag.2012.12.002. Epub 2013 Mar 16.

PMID:
23507004
34.

Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.

Shah BM, Schafer JJ, Priano J, Squires KE.

Pharmacotherapy. 2013 Oct;33(10):1107-16. doi: 10.1002/phar.1237. Epub 2013 Mar 7. Review.

PMID:
23471741
35.

Discussion: 'Comparison of cervical cancer screening strategies,' by Cox et al.

Hagemann AR, Wilkinson-Ryan I, Kuroki LM, Squires K.

Am J Obstet Gynecol. 2013 Mar;208(3):e1-4. doi: 10.1016/j.ajog.2013.01.036. Epub 2013 Jan 24.

PMID:
23353021
36.

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F, Kumar P, Thompson M, Campo RE, Mounzer K, Strohmaier KM, Lu C, Rodgers A, Jackson BE, Wenning LA, Robertson M, Nguyen BY, Sklar P; REALMRK Investigators.

AIDS Res Hum Retroviruses. 2013 Jun;29(6):859-70. doi: 10.1089/AID.2012.0292. Epub 2013 Feb 26.

37.

Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women.

Hermes A, Squires K, Fredrick L, Martinez M, Pasley M, Trinh R, Norton M.

HIV Clin Trials. 2012 Nov-Dec;13(6):308-23. doi: 10.1310/hct1306-308.

PMID:
23195669
38.

ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.

Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Ward D, Zhao HH, Ross LL, Shaefer MS; ARIES Study Team.

HIV Clin Trials. 2012 Sep-Oct;13(5):233-44. doi: 10.1310/hct1305-233.

PMID:
23134624
39.

Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE.

Smith KY, Garcia F, Kumar P, Currier JS, Ryan R, Falcon R, Mrus J, Squires K.

J Natl Med Assoc. 2012 Jul-Aug;104(7-8):366-76.

PMID:
23092052
40.

Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.

Young B, Squires KE, Ross LL, Santiago L, Sloan LM, Zhao HH, Wine BC, Pakes GE, Margolis DA, Shaefer MS; Aries EPZ108859 Study Team.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):350-8. doi: 10.1089/AID.2012.0278. Epub 2012 Dec 5.

41.

Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.

Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):390-9. doi: 10.1097/QAI.0b013e3182676fe3.

42.

Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women.

Kahn JA, Xu J, Zimet GD, Liu N, Gonin R, Dillard ME, Squires K; Adolescent Trials Network for HIV/AIDS Interventions.

J Adolesc Health. 2012 May;50(5):464-70. doi: 10.1016/j.jadohealth.2011.09.005. Epub 2011 Nov 4.

43.

Gender-sensitive reporting in medical research.

Heidari S, Abdool Karim Q, Auerbach JD, Buitendijk SE, Cahn P, Curno MJ, Hankins C, Katabira E, Kippax S, Marlink R, Marsh J, Marusic A, Nass HM, Montaner J, Pollitzer E, Ruiz-Cantero MT, Sherr L, Sow PS, Squires K, Wainberg MA.

J Int AIDS Soc. 2012 Mar 8;15(1):11. doi: 10.1186/1758-2652-15-11.

44.

Eptifibatide induced profound thrombocytopenia in a patient with pelvic malignancy: A case report.

Squires KC, Guntupalli SR, Thaker PH.

Gynecol Oncol Case Rep. 2012 Mar 14;2(3):75-7. doi: 10.1016/j.gynor.2012.03.002. eCollection 2012.

45.

Health-related quality of life in the gender, race, and clinical experience trial.

Feinberg J, Saag M, Squires K, Currier J, Ryan R, Coate B, Mrus J.

AIDS Res Treat. 2011;2011:349165. doi: 10.1155/2011/349165. Epub 2011 Aug 28.

46.

Prevalence of obstructive lung disease in HIV population: a cross sectional study.

Hirani A, Cavallazzi R, Vasu T, Pachinburavan M, Kraft WK, Leiby B, Short W, Desimone J, Squires KE, Weibel S, Kane GC.

Respir Med. 2011 Nov;105(11):1655-61. doi: 10.1016/j.rmed.2011.05.009. Epub 2011 Jun 23.

47.

Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study.

Falcon R, Bridge DA, Currier J, Squires K, Hagins D, Schaible D, Ryan R, Mrus J; GRACE Study Group.

J Womens Health (Larchmt). 2011 Jul;20(7):1043-50. doi: 10.1089/jwh.2010.2504. Epub 2011 Jun 10.

48.

Health needs of HIV-infected women in the United States: insights from the women living positive survey.

Squires KE, Hodder SL, Feinberg J, Bridge DA, Abrams S, Storfer SP, Aberg JA.

AIDS Patient Care STDS. 2011 May;25(5):279-85. doi: 10.1089/apc.2010.0228. Epub 2011 Mar 29.

49.

A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE; AIDS Clinical Trials Group (ACTG) 372A Study Team.

HIV Clin Trials. 2010 Nov-Dec;11(6):312-24. doi: 10.1310/hct1106-312.

50.

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.

Squires KE, Johnson M, Yang R, Uy J, Sheppard L, Absalon J, McGrath D.

J Antimicrob Chemother. 2011 Feb;66(2):363-70. doi: 10.1093/jac/dkq457. Epub 2010 Dec 9.

Supplemental Content

Loading ...
Support Center